BioViva Secures U.S. Patent for hTERT and Follistatin-344 Gene Therapy Approach to Age-Related Disorders

U.S. Patent No. 12,653,907 protects a dual-gene therapeutic strategy targeting telomere maintenance, muscle biology and metabolic function

SEATTLE, Sept. 10, 2026 /PRNewswire/ -- BioViva USA Inc. today announced the issuance of U.S. Patent No. 12,653,907, titled Methods of Treating or Preventing Age-Related Disorders, covering therapeutic methods involving the combination of human telomerase reverse transcriptase (hTERT) and Follistatin-344 (FST).

The patent was issued by the United States Patent and Trademark Office on June 16, 2026, BioViva USA Inc. is the assignee. The patent represents an important addition to BioViva's intellectual-property portfolio focused on genetic approaches to age-related disorders.

A Dual-Gene Approach to Age-Related Biology

The patented technology combines two biological targets with complementary roles in aging biology.

hTERT, the catalytic component of telomerase, is involved in telomere maintenance. Telomeres protect the ends of chromosomes and are associated with cellular replicative capacity and aging.

Follistatin-344, encoded by the FST gene, is a protein involved in biological pathways associated with muscle and tissue function.

The patent covers methods in which hTERT and Follistatin-344 are administered in combination for the treatment or prevention of age-related disorders. The issued claims include approaches associated with telomere length, muscle mass and blood-glucose levels.

The patent also encompasses genetic delivery approaches, including the use of viral vectors such as adeno-associated virus (AAV).

Building Intellectual Property Around Biological Aging

BioViva has pursued an intellectual-property strategy focused on targeting biological mechanisms associated with aging rather than addressing each age-related disease as an isolated condition.

The issuance of the Patent adds to BioViva's portfolio covering genetic approaches to age-related disorders and complements the company's intellectual property involving other longevity-associated pathways in humans.

"This patent represents an important milestone in BioViva's effort to develop a new category of medicine focused on the biology of aging," said Elizabeth Parrish, CEO of BioViva USA Inc. "We have been working for years to develop genetic approaches that address fundamental mechanisms associated with aging. Protecting the combination of hTERT and Follistatin-344 strengthens our ability to advance that work."

From Single-Disease Treatment to Aging Biology

Modern medicine has achieved remarkable advances by treating individual diseases. BioViva's approach is based on the premise that many chronic diseases of later life share biological processes that develop over decades.

Rather than waiting until those diseases become clinically apparent, BioViva is investigating whether genetic interventions directed at underlying biological mechanisms can become part of a broader strategy for maintaining human health and function.

The company's research and intellectual-property portfolio include programs involving telomere maintenance, tissue and muscle biology, metabolic regulation and cognitive decline.

A Growing Gene-Therapy Portfolio

The patent complements BioViva's existing intellectual property around genetic interventions for aging and age-related disease.

BioViva's portfolio includes intellectual property directed toward combinations of longevity-associated genes and therapeutic approaches intended to modulate biological pathways involved in age-related decline.

The company is continuing to develop its technology platform with the long-term objective of making advanced genetic and regenerative therapies available for diseases and conditions associated with aging.

"Aging is the greatest risk factor for many of the diseases that ultimately limit human healthspan," said Parrish. "Our goal is to move medicine upstream, to address the biology that contributes to age-related decline rather than simply treating its consequences one disease at a time."

About BioViva USA Inc.

BioViva USA Inc. is a biotechnology company developing genetic therapies intended to address biological mechanisms associated with aging and age-related disease. The company's research programs include genetic approaches involving telomere maintenance, tissue regeneration, metabolic pathways and cognitive function.

BioViva's mission is to advance genetic and regenerative technologies with the potential to extend healthy human lifespan and address diseases associated with biological aging.

Media Contact
BioViva USA Inc.
[email protected]
https://bioviva-science.com

The issuance of a patent does not constitute regulatory approval or establish the safety or efficacy of a therapeutic product. BioViva's technologies are investigational and remain subject to applicable preclinical, clinical and regulatory requirements.

SOURCE BioViva USA Inc.